Healthcare / Medical DevicesMilan
$16.10
+0.32 (+2.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $59.2M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
24.0x
↑EV/EBITDA
13.8x
↑ROE
10.5%
↑Gross Margin
42.9%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.3%
FCF CAGR
—
FCF margin
10.0%
FCF / Net income
1.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $590.8M · net income $43.4M · FCF $59.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $590.8M | $590.8M | $565.8M | $576.0M | $673.6M |
| Net Income | $43.4M | $43.4M | $51.6M | $48.2M | $55.1M |
| EBITDA | $85.5M | $85.5M | $97.3M | $88.1M | $89.5M |
| EPS | 0.53 | 0.53 | 0.63 | 0.60 | 0.69 |
| Gross Margin | 42.9% | 42.9% | 42.2% | 39.9% | 36.1% |
| Operating Margin | 12.2% | 12.2% | 12.7% | 12.8% | 11.2% |
| Net Margin | 7.3% | 7.3% | 9.1% | 8.4% | 8.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.12 | 0.21 | 0.26 |
| Cash Flow | |||||
| Free Cash Flow | $59.2M | $59.2M | $73.6M | $-1.4M | $-16.3M |
| Returns | |||||
| ROE | 10.5% | 10.5% | 13.4% | 13.9% | 17.6% |
| Valuation | |||||
| P/E | 24.03 | 24.03 | 17.65 | 15.81 | 20.91 |
| EV/EBITDA | 13.84 | 13.84 | 8.32 | 8.00 | 11.99 |
| P/B | 3.20 | 3.20 | 2.37 | 2.20 | 3.68 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | -1.8% | -14.5% | — |
| EPS Growth | -15.9% | -15.9% | 4.4% | -12.5% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
39.2%
EPS terminal req.
$1.43
Spread vs growth
-55.0%
5Y implied EPS CAGR
26.7%
EPS terminal req.
$1.73
Spread vs growth
-42.5%
10Y implied EPS CAGR
18.0%
EPS terminal req.
$2.78
Spread vs growth
-33.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+54.6%
Start / end P/E
16.7x → 30.4x
EPS bridge
0.63 → 0.53
Residual
-13.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.